These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25733352)

  • 1. Statistical approaches for the determination of cut points in anti-drug antibody bioassays.
    Schaarschmidt F; Hofmann M; Jaki T; Grün B; Hothorn LA
    J Immunol Methods; 2015 Mar; 418():84-100. PubMed ID: 25733352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [No Abstract]   [Full Text] [Related]  

  • 4. A new method for identification of outliers in immunogenicity assay cut point data.
    Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
    J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing efficiency and quality of statistical estimation of immunogenicity assay cut points through standardization and automation.
    Su C; Zhou L; Hu Z; Weng W; Subramani J; Tadkod V; Hamilton K; Bautista A; Wu Y; Chirmule N; Zhong ZD
    J Immunol Methods; 2015 Oct; 425():88-96. PubMed ID: 26130368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of in-study cut points to enable appropriate interpretation of clinical immunogenicity results.
    Brumm J; Peng K
    Bioanalysis; 2019 Sep; 11(17):1539-1541. PubMed ID: 31208203
    [No Abstract]   [Full Text] [Related]  

  • 9. Statistical Approaches for Establishing Appropriate Immunogenicity Assay Cut Points: Impact of Sample Distribution, Sample Size, and Outlier Removal.
    Garlits J; McAfee S; Taylor JA; Shum E; Yang Q; Nunez E; Kameron K; Fenech K; Rodriguez J; Torri A; Chen J; Sumner G; Partridge MA
    AAPS J; 2023 Apr; 25(3):37. PubMed ID: 37016171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.
    Devanarayan V; Smith WC; Brunelle RL; Seger ME; Krug K; Bowsher RR
    AAPS J; 2017 Sep; 19(5):1487-1498. PubMed ID: 28733862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity assay cut point determination using nonparametric tolerance limit.
    Zhang J; Li W; Roskos LK; Yang H
    J Immunol Methods; 2017 Mar; 442():29-34. PubMed ID: 28063769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
    Shen M; Dong X; Tsong Y
    J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical methods of screening cut point determination in immunogenicity studies.
    Shen M; Dai T
    Bioanalysis; 2021 Apr; 13(7):551-563. PubMed ID: 33755515
    [No Abstract]   [Full Text] [Related]  

  • 14. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Singer J; Allacher P; Horling F
    J Pharm Biomed Anal; 2011 Jul; 55(5):1148-56. PubMed ID: 21561734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution.
    Schlain B; Amaravadi L; Donley J; Wickramasekera A; Bennett D; Subramanyam M
    J Immunol Methods; 2010 Jan; 352(1-2):161-8. PubMed ID: 19891969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing drug effects on cut point determination for an anti-drug antibody assay.
    Barbosa MD; Gleason CR; Phillips KR; Berisha F; Stouffer B; Warrack BM; Chen G
    J Immunol Methods; 2012 Oct; 384(1-2):152-6. PubMed ID: 22750627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?
    Jaki T; Allacher P; Horling F
    J Pharm Biomed Anal; 2016 Sep; 128():166-173. PubMed ID: 27262992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Memory B Activity Against a Therapeutic Protein in Treatment-Naïve Subjects.
    Liao K; Derbyshire S; Wang KF; Caucci C; Tang S; Holland C; Loercher A; Gunn GR
    AAPS J; 2018 Mar; 20(3):51. PubMed ID: 29549534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population.
    Tan CY; Steeno GS; You Z; Gaitonde P; Cai CH; Kamerud J; Gorovits B; Baltrukonis DJ
    AAPS J; 2020 Jan; 22(2):19. PubMed ID: 31900604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.